TY - JOUR
T1 - Risk and incidence of head and neck cancers in veterans living with HIV and matched HIV-negative veterans
AU - Mazul, Angela L.
AU - Hartman, Christine M.
AU - Mowery, Yvonne M.
AU - Kramer, Jennifer R.
AU - White, Donna L.
AU - Royse, Kathryn E.
AU - Raychaudhury, Suchismita
AU - Sandulache, Vlad C.
AU - Ahmed, Sarah T.
AU - Zevallos, Jose P.
AU - Richardson, Peter A.
AU - Sikora, Andrew G.
AU - Chiao, Elizabeth Y.
N1 - Funding Information:
The manuscript was edited by the Scientific Editing Service of the Institute of Clinical and Translational Sciences at Washington University, which is supported by an NIH Clinical and Translational Science Award (UL1 TR002345). This research was supported by the National Cancer Institute (R01CA206476 to Elizabeth Y. Chiao and Jennifer R. Kramer), the Houston Veterans Affairs Health Services Research and Development Center of Innovations (CIN13‐413), the Dan L. Duncan Cancer Center (P30CA125123), the National Institute of Minority Health and Health Disparities (K01MD013897 to Angela L. Mazul), the US Department of Veterans Affairs (CX001430 to Donna L. White), the National Institute of Dental and Craniofacial Research (to Yvonne M. Mowery), and the US Department of Veterans Affairs Clinical Sciences Research and Development Program (IK2 CX001953 to Vlad C. Sandulache). The funders had no role in study design, interpretation, or publishing.
Funding Information:
Christine M. Hartman is an independent contractor/consultant for Baylor College of Medicine. Angela L. Mazul reports travel funding from Augusta University. Yvonne M. Mowery is an independent contractor/consultant for Oakstone CME and UpToDate. Andrew G. Sikora is an independent contractor/consultant for F. Hoffmann‐La Roche. Jose P. Zevallos is a founder and equity shareholder in Droplet Biosciences and an equity shareholder in Summit Biolabs. The other authors made no disclosures.
Publisher Copyright:
© 2022 American Cancer Society.
PY - 2022/9/15
Y1 - 2022/9/15
N2 - Background: Persons living with HIV/AIDS have a higher incidence of virus-related and tobacco/alcohol-related cancers. This study is the first to estimate the effect of HIV versus HIV-negative veterans on the risk of head and neck squamous cell carcinoma incidence in a large retrospective cohort study. Methods: The authors constructed a retrospective cohort study using patient data from 1999 to 2016 from the National Veterans Administration Corporate Data Warehouse and the VA Central Cancer Registry. This cohort study included 45,052 veterans living with HIV/AIDS and 162,486 HIV-negative patients matched by age, sex, and index visit (i.e., HIV diagnosis date or clinic visit date). The age-standardized incidence rates and estimated adjusted hazard ratios were calculated with a Cox proportional hazards regression for oropharyngeal and nonoropharyngeal head and neck cancer squamous cell carcinoma (HNSCC). The authors also abstracted human papillomavirus (HPV) status from oropharyngeal HNSCC diagnosed after 2010. Results: Veterans living with HIV/AIDS (VLWH) have 1.71 (95% confidence interval [CI], 1.36, 2.14) times the risk of oropharyngeal cancer and 2.06 (95% CI, 1.76, 2.42) times the hazard of nonoropharyngeal cancer compared with HIV-negative veterans. VLWH with oropharyngeal squamous cell carcinoma (OPSCC) were more likely to be HPV-positive (N = 30 [81.1%]) than the HIV-negative veterans with OPSCC (N = 50 [67.6%]), although this difference was not significant (p =.135). For nonoropharyngeal cancer, the increased risk of oral cavity cancer among VLWH drove the increased risk. Conclusions: The study results suggest that HIV may play a role in virally mediated and nonvirally mediated HNSCC. As the HIV prevalence rises in the United States due to better survival and the incidence of HPV-positive oropharyngeal HNSCC increases, the interaction between HPV and HIV becomes increasingly relevant.
AB - Background: Persons living with HIV/AIDS have a higher incidence of virus-related and tobacco/alcohol-related cancers. This study is the first to estimate the effect of HIV versus HIV-negative veterans on the risk of head and neck squamous cell carcinoma incidence in a large retrospective cohort study. Methods: The authors constructed a retrospective cohort study using patient data from 1999 to 2016 from the National Veterans Administration Corporate Data Warehouse and the VA Central Cancer Registry. This cohort study included 45,052 veterans living with HIV/AIDS and 162,486 HIV-negative patients matched by age, sex, and index visit (i.e., HIV diagnosis date or clinic visit date). The age-standardized incidence rates and estimated adjusted hazard ratios were calculated with a Cox proportional hazards regression for oropharyngeal and nonoropharyngeal head and neck cancer squamous cell carcinoma (HNSCC). The authors also abstracted human papillomavirus (HPV) status from oropharyngeal HNSCC diagnosed after 2010. Results: Veterans living with HIV/AIDS (VLWH) have 1.71 (95% confidence interval [CI], 1.36, 2.14) times the risk of oropharyngeal cancer and 2.06 (95% CI, 1.76, 2.42) times the hazard of nonoropharyngeal cancer compared with HIV-negative veterans. VLWH with oropharyngeal squamous cell carcinoma (OPSCC) were more likely to be HPV-positive (N = 30 [81.1%]) than the HIV-negative veterans with OPSCC (N = 50 [67.6%]), although this difference was not significant (p =.135). For nonoropharyngeal cancer, the increased risk of oral cavity cancer among VLWH drove the increased risk. Conclusions: The study results suggest that HIV may play a role in virally mediated and nonvirally mediated HNSCC. As the HIV prevalence rises in the United States due to better survival and the incidence of HPV-positive oropharyngeal HNSCC increases, the interaction between HPV and HIV becomes increasingly relevant.
KW - Veterans Health Administration
KW - head and neck cancer
KW - incidence
KW - non–AIDS-defining cancers
KW - people living with HIV/AIDS
UR - http://www.scopus.com/inward/record.url?scp=85134571190&partnerID=8YFLogxK
U2 - 10.1002/cncr.34387
DO - 10.1002/cncr.34387
M3 - Article
C2 - 35867552
AN - SCOPUS:85134571190
SN - 0008-543X
VL - 128
SP - 3310
EP - 3318
JO - Cancer
JF - Cancer
IS - 18
ER -